Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J. Blackstone J, et al. Among authors: arun t. BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article. Clinical Trial.
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.
Rashid W, Ciccarelli O, Leary SM, Arun T, Doshi A, Evangelou N, Ford HL, Hobart J, Jacob S, Muraro PA, Murray K, Palace J, Dobson R; Association Of British Neurologists Multiple Sclerosis and Neuroinflammation Advisory Group. Rashid W, et al. Among authors: arun t. Pract Neurol. 2024 Nov 11:pn-2024-004228. doi: 10.1136/pn-2024-004228. Online ahead of print. Pract Neurol. 2024. PMID: 39532459 Review.
Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis.
Armoiry X, Wang-Steverding X, Connock M, Grove A, Clarke A, Arun T, Counsell C, Auguste P. Armoiry X, et al. Among authors: arun t. Int J Technol Assess Health Care. 2022 Dec 13;38(1):e83. doi: 10.1017/S0266462322003269. Int J Technol Assess Health Care. 2022. PMID: 36510406 Review.
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty.
Arun T, Petheram K, Tallantyre E, Ford H, Chataway J, Dougall NM, Doshi A, Englezou C, Farrell R, Hughes S, McDonnell G, Murray K, Rees R, Robertson N, Schmierer K, Dobson R; Association of British Neurologists, Special interest group for MS and neuroinflammation. Arun T, et al. Mult Scler Relat Disord. 2024 Dec;92:106144. doi: 10.1016/j.msard.2024.106144. Epub 2024 Nov 10. Mult Scler Relat Disord. 2024. PMID: 39579643
91 results